发明名称 Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery
摘要 The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, m) of 100-500 nm, wherein the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc. The emulsion formulations and method of manufacturing significantly improves the stability of clopidogrel over other aqueous based formulations (such as cyclodextrin-based formulations and emulsion made using clopidogrel salt as the starting materials) with respect to chiral degradation, hydrolytic, and thermal degradation. Ready-to-use emulsion compositions, which can be administered orally or parentally as a single high dose with up to 300 mg of clopidogrel dose, can be prepared and stored at room temperature for at least 19 weeks or at refrigeration temperature for at least 1 year. The compositions will provide rapid therapeutic action as anti-platelet agent for patient under emergence and intense care or who cannot swallow tablet dosage form.
申请公布号 US9480680(B2) 申请公布日期 2016.11.01
申请号 US201414174351 申请日期 2014.02.06
申请人 Huang Jingjun 发明人 Huang Jingjun
分类号 A61K9/14;A61K31/44;A61K31/4365;A61K9/107;A61K47/10;A61K47/14;A61K47/44;A61K9/00 主分类号 A61K9/14
代理机构 Gearhart Law, LLC. 代理人 Gearhart Law, LLC.
主权项 1. A stable pharmaceutical oil-in-water emulsion composition in a liquid form with nanosized oil droplets for parenteral or oral administration comprising: clopidogrel free base encapsulated in an oil phase of said emulsion; a surfactant and an optional co-surfactant; a water phase substantially free of clopidogrel; and a pH adjusting agent; wherein the oil phase is about 1 to 30% (w/w) of the composition, and the total weight of the surfactant and the optional co-surfactant is 0.5-6% (w/v) of the composition; and wherein the clopidogrel free base comprises about 0.15% to about 10% (w/v) of the composition and has an overall purity of at least 97.5% maintained for at least six months, wherein the mean droplet size (intensity-average, nm) is 100-500 nm.
地址 Monmouth Junction NJ US
您可能感兴趣的专利